@incollection{,
	
					
					
					038C5A48BF04C47E69F5A020A64E3C74
				,
	author={{PranabMaiti} and {RajivSharma}},
	journal={{Global Journal of Medical Research}},
	journal={{GJMR}}2249-46180975-588810.34257/GJMR,
	address={Cambridge, United States},
	publisher={Global Journals Organisation}211110
}

@incollection{b0,
	
	
		,
	title={{The global burden of IBD: from 2015 to 2025}}
		,
	author={{
			GGKaplan
		}}
	
	
		,
	journal={{Nat Rev Gastro Hepatol}}
		
			12
			
			,
	year={2015}
		
	

}

@incollection{b1,
	
	
		,
	title={{Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences}}
		,
	author={{
			EVLoftusJr
		}}
	
	
		,
	journal={{Gastroenterology}}
		
			126
			
			,
	year={2004}
		
	

}

@incollection{b2,
	
	
		,
	title={{Clinical aspects and pathophysiology of inflammatory bowel syndrome}}
		,
	author={{
			BAHendrickson
		} and {
			RGokhale
		} and {
			JHCho
		}}
		
		
	
	
		,
	journal={{Clin Microbiol Rev}}
		
			
			,
	year={2002}
		
	

}

@incollection{b3,
	
	
		,
	title={{An overview of inflammatory bowel disease unclassified in children}}
		,
	author={{
			LEThurgate
		} and {
			DALemberg
		} and {
			ASDay
		}}
		
		
	
	
		,
	journal={{Inflamm Intest Dis}}
		
			4
			
			,
	year={2019}
		
	

}

@incollection{b4,
	
	
		,
	title={{Ecological and evolutionary forces shaping microbial diversity in the human intestine}}
		,
	author={{
			LERay
		} and {
			PetersonDa
		} and {
			JIGordon
		}}
		
		
	
	
		,
	journal={{Cell}}
		
			124
			
			,
	year={2006}
		
	

}

@incollection{b5,
	
	
		,
	title={{Epithelial cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut}}
		,
	author={{
			DArtis
		}}
	
	
		,
	journal={{Nat Rev Immun}}
		
			8
			
			,
	year={2008}
		
	

}

@incollection{b6,
	
	
		,
	title={{Ulcerative colitis and colorectal cancer: a population-based study}}
		,
	author={{
			AEkbom
		} and {
			CHelmick
		} and {
			MZack
		}}
		
		
	
	
		,
	journal={{New Eng J Med}}
		
			323
			
			,
	year={1990}
		
	

}

@incollection{b7,
	
	
		,
	title={{Cytokines in inflammatory bowel disease}}
		,
	author={{
			FNMarkus
		}}
	
	
		,
	journal={{Nat Rev Immun}}
		
			
			,
	year={2014}
		
	

}

@incollection{b8,
	
	
		,
	title={{Novel therapies and treatment strategies for patients with inflammatory bowel disease}}
		,
	author={{
			MDuijvestein
		} and {
			RBattat
		} and {
			CNCande
		}}
		
		
	
	
		,
	journal={{Current Treatment Options in Gastroenterology}}
		
			16
			
			,
	year={2018}
		
	

}

@incollection{b9,
	
	
		,
	title={{Mechanism-Based Treatment Strategies for IBD: Cytokines}}
		,
	author={{
			PSchreiner
		} and {
			MFNeurath
		} and {
			SCNg
		}}
		
		
	
	
		,
	journal={{JAK Inhibitors, Gut Flora, and More. Inflam Intest Dis}}
		
			4
			
			,
	year={2019}
		
	
	,
	note={Cell Adhesion Molecules}

}

@incollection{b10,
	
	
		,
	title={{Inflammatory bowel disease: clinical aspects and treatments}}
		,
	author={{
			MFakhoury
		} and {
			RNegrulj
		} and {
			AMooranian
		}}
		
		
	
	
		,
	journal={{J Inflamm Res}}
		
			7
			
			,
	year={2014}
		
	

}

@incollection{b11,
	
	
		,
	title={{Efficacy and Safety of Anti-Interleukin-23 Therapy with Mirikizumab (LY3074828) in Patients with Moderate-To-Severe Ulcerative Colitis in a Phase 2 Study}}
		,
	author={{
			WJSandborn
		} and {
			MFerrante
		} and {
			BRBhandari
		}}
		
		
	
	
		,
	journal={{Gastroenterology}}
		
			154
			
			,
	year={2018}
		
	

}

@incollection{b12,
	
	
		,
	title={{IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting}}
		,
	author={{
			AMoschen
		} and {
			HTilg
		} and {
			TRaine
		}}
		
		
	
	
		,
	journal={{Nat. Rev. Gastro. Hep}}
		
			16
			
			,
	year={2019}
		
	

}

@incollection{b13,
	
	
		,
	title={{Computational modeling-based discovery of novel classes of antiinflammatory drugs that target lanthionine synthetase C-like protein 2}}
		,
	author={{
			PLu
		} and {
			RHontecillas
		} and {
			WTHorne
		}}
		
		
	
	
		,
	journal={{PLOS one}}
		
			7
			e34643
			,
	year={2012}
		
	

}

@incollection{b14,
	
	
		,
	title={{Exploratory studies with BT-11: a proposed orally active therapeutic for Crohn's Disease}}
		,
	author={{
			PBissell
		} and {
			KBoes
		} and {
			JHinkley
		}}
		
		
	
	
		,
	journal={{Int J Tox}}
		
			35
			
			,
	year={2016}
		
	

}

@incollection{b15,
	
	
		,
	title={{Activation of LANCL2 by BT-11 ameliorates IBD by supporting regulatory T Cell stability through immunometabolic mechanisms}}
		,
	author={{
			ALeber
		} and {
			RHontecillas
		} and {
			VZoccoli-Rodriguez
		}}
		
		
	
	
		,
	journal={{Inflam Bowel Dis}}
		
			24
			
			,
	year={2018}
		
	

}

@incollection{b16,
	
	
		,
	title={{The Safety, tolerability, and pharmacokinetics profile of BT-11, an oral, gut-restricted Lanthionine Synthetase C-Like 2 agonist investigational new drug for inflammatory boweldisease: a randomized, double-blind, placebo-controlled phase I clinical trial}}
		,
	author={{
			ALeber
		} and {
			RHontecillas
		} and {
			VZoccoli-Rodriguez
		}}
		
		
	
	
		,
	journal={{Inflam Bowel Dis}}
		
			26
			
			,
	year={2020}
		
	

}

@book{b17,
	
	
		,
	title={{}}
		,
	author={{
			MMurphy
		} and {
			YXiong
		} and {
			GPattabiraman
		}}
		
		
		
	

}

@incollection{b18,
	
	
		,
	title={{Positively Regulates Toll-like Receptor (TLR) 2 and TLR4 Signaling and Is Suppressed upon Induction of Endotoxin Tolerance}}
	
	
		,
	journal={{J Biol Chem}}
		
			290
			
			,
	year={2015}
		
	

}

@incollection{b19,
	
	
		,
	title={{BBT-401 is a selective Pellino-1 protein-protein interaction inhibitor in clinical development targeting a first-in-class drug for UC treatment}}
		,
	author={{
			GLee
		} and {
			YLee
		} and {
			MChang
		}}
		
		
	
	
		,
	journal={{Inflam Bowel Dis}}
		
			25
			S58
			,
	year={2019}
		
	

}

@book{b20,
	
	
		,
	title={{News from the Crohn's and Colitis Congress}}
		
			,
	year={Feb 2019}
			,
	address={Las Vegas}
		
	

}

@incollection{b21,
	
	
		,
	title={{Adherentinvasive Escherichia Coli in inflammatory bowel disease}}
		,
	author={{
			CPalmela
		} and {
			CChevarin
		} and {
			ZXu
		}}
		
		
	
	
		,
	journal={{Gut}}
		
			67
			
			,
	year={2018}
		
	

}

@incollection{b22,
	
	
		,
	title={{A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131}}
		,
	author={{
			MTotsika
		} and {
			MKostakioti
		} and {
			TJHannan
		}}
		
		
	
	
		,
	journal={{J Infec Dis}}
		
			208
			
			,
	year={2013}
		
	

}

@book{b23,
	
	
		,
	title={{Rational design strategies for FimH antagonists: new drugs on the horizon for urimary tract infection and Crohn's Disease. Exp Opin Drug Disc}}
		,
	author={{
			LMydock-Mcgrane
		} and {
			TJHannan
		} and {
			JWJenetka
		}}
		
		
		
			,
	year={2017}
			12
			
		
	

}

@incollection{b24,
	
	
		,
	title={{The Antiadhesive strategy in Crohn?s Disease: orally active mannosides to decolonize pathogenic escherichia coli from the gut}}
		,
	author={{
			DDAlvarez
		} and {
			ASivignon
		} and {
			TChalopini
		}}
		
		
	
	
		,
	journal={{ChemBioChem}}
		
			17
			
			,
	year={2016}
		
	

}

@incollection{b25,
	
	
		,
	title={{AVX470 -a novel oral anti TNF antibody with therapeutic potential in inflammatory bowel disease}}
		,
	author={{
			KCBhol
		} and {
			DETracey
		} and {
			BRLemos
		}}
		
		
	
	
		,
	journal={{Inflam Bowel Dis}}
		
			19
			
			,
	year={2013}
		
	

}

@incollection{b26,
	
	
		,
	title={{AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment for acute ulcerative colitis: results of a first-in-human trial}}
		,
	author={{
			MSHarris
		} and {
			DHartman
		} and {
			BRLemos
		}}
		
		
	
	
		,
	journal={{J Crohns Colitis}}
		
			10
			
			,
	year={2016}
		
	

}

@incollection{b27,
	
	
		,
	title={{The hypoxiaadenosine link during intestinal inflammation}}
		,
	author={{
			JLBowser
		} and {
			LHPhan
		} and {
			HKEltzschig
		}}
		
		
	
	
		,
	journal={{J Immun}}
		
			200
			
			,
	year={2018}
		
	

}

@incollection{b28,
	
	
		,
	title={{Regulation of IL-12p40 by HIF Controls Th1/Th17 Responses to Prevent Mucosal Inflammation}}
		,
	author={{
			EMarks
		} and {
			CNaudin
		} and {
			GNolan
		}}
		
		
	
	
		,
	journal={{Mucosal Immunol}}
		
			10
			
			,
	year={2017}
		
	

}

@incollection{b29,
	
	
		,
	title={{Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis}}
		,
	author={{
			SKeely
		} and {
			ELCampbell
		} and {
			AWBaird
		}}
		
		
	
	
		,
	journal={{Mucosal Immunol}}
		
			22
			
			,
	year={2014}
		
	

}

@incollection{b30,
	
	
		,
	title={{Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis}}
		,
	author={{
			EMarks
		} and {
			BJGoggins
		} and {
			JCordona
		}}
		
		
	
	
		,
	journal={{Inflam Bowel Dis}}
		
			21
			
			,
	year={2015}
		
	

}

@incollection{b31,
	
	
		,
	title={{Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability}}
		,
	author={{
			AJKing
		} and {
			MSiegel
		} and {
			YHe
		}}
		
		
	
	
		,
	journal={{Sci Transl Med}}
		
			10
			456
			,
	year={2018}
		
	

}

@incollection{b32,
	
	
		,
	title={{Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)}}
		,
	author={{
			WDChey
		} and {
			AJLembo
		} and {
			DPRosenbaum
		}}
		
		
	
	
		,
	journal={{Am J Gastro}}
		
			115
			
			,
	year={2020}
		
	

}

@incollection{b33,
	
	
		,
	title={{Tu1744 -Targeted release oral cyclosporine (ST-0529) as a potential new therapy for ulcerative colitis: Phase I study results}}
		,
	author={{
			JFColombel
		} and {
			JHall
		} and {
			MRosa
		}}
		
		
	
	
		,
	journal={{Gastro}}
		
			156
			S1108
			,
	year={2019}
		
	

}